Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy

Oncology Nursing Forum

Volumn 34, Issue 2, 2007, Pages 301-304

  Reilly, Margaret M ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE NECROSIS; BONE TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HUMAN; MALE; MANDIBLE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; MALE; MANDIBLE; OSTEONECROSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34548458463     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/07.ONF.301-305     Document Type: Article

References (12)

1. Assouline-Dayan, Y., Chang, C., Greenspan, A., Shoenfeld, Y., & Gershwin, M.E. (2002). Pathogenesis and natural history of osteonecrosis. Seminars in Arthritis and Rheumatism, 32, 94-124.
2. Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L.A., Melakopoulos, I., Bozas, G., et al. (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. Journal of Clinical Oncology, 23, 8580-8587.
3. Hellstein, J.W., & Marek, C.L. (2005). Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? Journal of Oral and Maxillofacial Surgery, 63, 682-689.
4. Marx, R.E., Sawatari, Y., Fortin, M., & Broumand, V. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery, 63, 1567-1575.
5. Migliorati, C.A., Casiglia, J., Epstein, J., Jacobsen, P.L., Siegel, M.A., & Woo, S.B. (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. Journal of the American Dental Association, 136, 1658-1668.
6. Migliorati, C.A., Schubert, M.M., Peterson, D.E., & Seneda, L.M. (2005). Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer, 104, 83-93.
7. National Cancer Institute. (2006). Cancer Therapy Evaluation Program: Common terminology cri teria for adverse events, version 3.0. Retrieved November 28, 2006, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
8. Novartis. (2006). Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients: May 2006. Retrieved December 1, 2006, from http://www.novartis.co.jp/product/zom/te/ te_arezom0607_a.html
9. Ruggiero, S., Gralow, J., Marx, R., Hoff, A., Schubert, M., Huryn, J., et al. (2006). Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Clinical Practice, 2(1), 7-14.
10. Woo, S.K., Hellstein, J.W., & Kalmar, J.R. (2006). Systematic review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144, 753-761.
11. Wood, J., Bonjean, K., Ruetz, S., Bellahcene, A., Devy, L., Foidart, J.M., et al. (2002). Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. Journal of Pharmacology and Experimental Therapeutics, 302, 1055-1061.
12. Zarychanski, R., Elphee, E., Walton, P., & Johnston, J. (2006). Osteonecrosis of the jaw associated with pamidronate therapy. American Journal of Hematology, 81, 73-75.